Sabzevari Helen Insider Trading Activity (PGEN)

Summary

Updated Jul 16, 2026

Sabzevari Helen has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.56M.

Profile

Helen Sabzevari is the President and CEO of Precigen, Inc., a biotechnology company focused on synthetic biology solutions. She has held various leadership roles within the company and is known for her contributions to the development of gene programs and biotechnology innovations.

Role	President and CEO
Notability	50/100

Board memberships

Precigen, Inc.

Awards & honors

Leadership in biotechnology innovation
Development of synthetic biology solutions
Role in advancing gene therapy technologies

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-07-01	PGEN	PRECIGEN, INC.	S — Open-market sale	346.8K	$5.89	$2.04M
2026-07-01	PGEN	PRECIGEN, INC.	M — Option exercise	346.8K	$2.33	$808K
2026-06-01	PGEN	PRECIGEN, INC.	S — Open-market sale	119.2K	$4.36	$520K
2026-05-28	PGEN	PRECIGEN, INC.	M — Option exercise	250.0K	—
2026-03-20	PGEN	PRECIGEN, INC.	M — Option exercise	321.1K	—

Frequently Asked Questions

Who is Sabzevari Helen?

How many SEC Form 4 filings has Sabzevari Helen submitted recently?

4 primary Form 4 filings in the last 90 days, covering 1 company.

Has Sabzevari Helen been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 2 open-market sales ($2.56M) across all tracked filings.

Where can I see all of Sabzevari Helen's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Sabzevari Helen — SEC Form 4 Insider Trading Activity